Literature DB >> 28239158

Synthesis of the novel PARP-1 inhibitor AG-690/11026014 and its protective effects on angiotensin II-induced mouse cardiac remodeling.

Guo-Shuai Feng1, Cui-Ge Zhu2, Zhuo-Ming Li1, Pan-Xia Wang1, Yi Huang1, Min Liu3, Ping He1, Lan-Lan Lou2, Shao-Rui Chen1, Pei-Qing Liu1.   

Abstract

We previously identified AG-690/11026014 (6014) as a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor that effectively prevented angiotensin II (Ang II)-induced cardiomyocyte hypertrophy. In the present study, we reported a new synthesis route for 6014, and investigated its protective effects on Ang II-induced cardiac remodeling and cardiac dysfunction and the underlying mechanisms in mice. We designed a new synthesis route to obtain a sufficient quantity of 6014 for this in vivo study. C57BL/6J mice were infused with Ang II and treated with 6014 (10, 30, 90 mg·kg-1·d-1, ig) for 4 weeks. Then two-dimensional echocardiography was performed to assess the cardiac function and structure. Histological changes of the hearts were examined with HE staining and Masson's trichrome staining. The protein expression was evaluated by Western blot, immunohistochemistry and immunofluorescence assays. The activities of sirtuin-1 (SIRT-1) and the content of NAD+ were detected with the corresponding test kits. Treatment with 6014 dose-dependently improved cardiac function, including LVEF, CO and SV and reversed the changes of cardiac structure in Ang II-infused mice: it significantly ameliorated Ang II-induced cardiac hypertrophy evidenced by attenuating the enlargement of cardiomyocytes, decreased HW/BW and LVW/BW, and decreased expression of hypertrophic markers ANF, BNP and β-MHC; it also prevented Ang II-induced cardiac fibrosis, as implied by the decrease in excess accumulation of extracellular matrix (ECM) components collagen I, collagen III and FN. Further studies revealed that treatment with 6014 did not affect the expression levels of PARP-1, but dose-dependently inhibited the activity of PARP-1 and subsequently restored the activity of SIRT-1 in heart tissues due to the decreased consumption of NAD+ and attenuated Poly-ADP-ribosylation (PARylation) of SIRT-1. In conclusion, the novel PARP-1 inhibitor 6014 effectively protects mice against AngII-induced cardiac remodeling and improves cardiac function. Thus, 6014 might be a potential therapeutic agent for heart diseases..

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28239158      PMCID: PMC5457692          DOI: 10.1038/aps.2016.159

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  38 in total

1.  Poly(ADP-ribose) polymerase-1-deficient mice are protected from angiotensin II-induced cardiac hypertrophy.

Authors:  Jyothish B Pillai; Madhu Gupta; Senthilkumar B Rajamohan; Roberto Lang; Jai Raman; Mahesh P Gupta
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-04-21       Impact factor: 4.733

2.  Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats.

Authors:  Matthew J Huentelman; Justin L Grobe; Jorge Vazquez; Jillian M Stewart; Adam P Mecca; Michael J Katovich; Carlos M Ferrario; Mohan K Raizada
Journal:  Exp Physiol       Date:  2005-07-27       Impact factor: 2.969

3.  Intra-mitochondrial poly(ADP-ribosylation) contributes to NAD+ depletion and cell death induced by oxidative stress.

Authors:  Lina Du; Xiaopeng Zhang; Yong Y Han; Nancy A Burke; Patrick M Kochanek; Simon C Watkins; Steven H Graham; Joseph A Carcillo; Csaba Szabó; Robert S B Clark
Journal:  J Biol Chem       Date:  2003-03-07       Impact factor: 5.157

Review 4.  On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1.

Authors:  Xin Luo; W Lee Kraus
Journal:  Genes Dev       Date:  2012-03-01       Impact factor: 11.361

5.  PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway.

Authors:  Anita Palfi; Ambrus Toth; Katalin Hanto; Peter Deres; Eszter Szabados; Zoltan Szereday; Gyozo Kulcsar; Tamas Kalai; Kalman Hideg; Ferenc Gallyas; Balazs Sumegi; Kalman Toth; Robert Halmosi
Journal:  J Mol Cell Cardiol       Date:  2006-05-23       Impact factor: 5.000

6.  PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats.

Authors:  Eva Bartha; Izabella Solti; Laszlo Kereskai; Janos Lantos; Eniko Plozer; Klara Magyar; Eszter Szabados; Tamás Kálai; Kálmán Hideg; Robert Halmosi; Balazs Sumegi; Kalman Toth
Journal:  Cardiovasc Res       Date:  2009-05-14       Impact factor: 10.787

7.  Are poly(ADP-ribosyl)ation by PARP-1 and deacetylation by Sir2 linked?

Authors:  Jie Zhang
Journal:  Bioessays       Date:  2003-08       Impact factor: 4.345

Review 8.  Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.

Authors:  J N Cohn; R Ferrari; N Sharpe
Journal:  J Am Coll Cardiol       Date:  2000-03-01       Impact factor: 24.094

Review 9.  Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system.

Authors:  K T Weber; C G Brilla
Journal:  Circulation       Date:  1991-06       Impact factor: 29.690

10.  PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation.

Authors:  Péter Bai; Carles Cantó; Hugues Oudart; Attila Brunyánszki; Yana Cen; Charles Thomas; Hiroyasu Yamamoto; Aline Huber; Borbála Kiss; Riekelt H Houtkooper; Kristina Schoonjans; Valérie Schreiber; Anthony A Sauve; Josiane Menissier-de Murcia; Johan Auwerx
Journal:  Cell Metab       Date:  2011-04-06       Impact factor: 27.287

View more
  5 in total

Review 1.  SIRT1 and SIRT6 Signaling Pathways in Cardiovascular Disease Protection.

Authors:  Nunzia D'Onofrio; Luigi Servillo; Maria Luisa Balestrieri
Journal:  Antioxid Redox Signal       Date:  2017-06-29       Impact factor: 8.401

2.  PARP1 interacts with HMGB1 and promotes its nuclear export in pathological myocardial hypertrophy.

Authors:  Qian Li; Zhuo-Ming Li; Shu-Ya Sun; Lu-Ping Wang; Pan-Xia Wang; Zhen Guo; Han-Wei Yang; Jian-Tao Ye; Jing Lu; Pei-Qing Liu
Journal:  Acta Pharmacol Sin       Date:  2018-07-20       Impact factor: 6.150

3.  SIRT3 inhibits cardiac hypertrophy by regulating PARP-1 activity.

Authors:  Xiaojun Feng; Yanan Wang; Wenxu Chen; Suowen Xu; Lingli Li; Yadi Geng; Aizong Shen; Hui Gao; Lei Zhang; Sheng Liu
Journal:  Aging (Albany NY)       Date:  2020-03-04       Impact factor: 5.682

4.  The poly(ADP-ribosyl)ation of BRD4 mediated by PARP1 promoted pathological cardiac hypertrophy.

Authors:  Zhenzhen Li; Zhen Guo; Rui Lan; Sidong Cai; Zhirong Lin; Jingyan Li; Junjian Wang; Zhuoming Li; Peiqing Liu
Journal:  Acta Pharm Sin B       Date:  2020-12-14       Impact factor: 11.413

Review 5.  Programmed necrosis in cardiomyocytes: mitochondria, death receptors and beyond.

Authors:  Junxia Zhang; Dairu Liu; Mao Zhang; Yan Zhang
Journal:  Br J Pharmacol       Date:  2018-06-25       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.